Philipp Schreiner
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Philipp Schreiner has a total of 211 co-authors. Here are the top co-authors by number of shared publications:
Luc Biedermann
Department of Gastroenterology and Hepatology, University Hospital Zürich , Zürich
17 shared publicationsThomas Greuter
Division of Gastroenterology and Hepatology, EOC Lugano, Università della Svizzera italiana , Lugano
11 shared publicationsAlex Straumann
Department of Gastroenterology and Hepatology, University Hospital Zürich , Zürich
9 shared publicationsAlain Schoepfer
Division of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne , Lausanne
7 shared publications- Benjamin Misselwitz
Department of Visceral Surgery and Medicine, Bern University Hospital, University of Bern, Bern, Switzerland
7 shared publications Gerhard Rogler
Department of Gastroenterology and Hepatology, University Hospital Zürich , Zürich
7 shared publications
Latest Publications
- Open Access
- 27 October 2026
- Published by Wiley in Alimentary Pharmacology & Therapeutics
Colonic Mast Cell Density and Diarrhoea: Evidence Against a Threshold Effect in Biopsies From 3508 Patients
Background: Elevated mast cell (MC) counts in colonic biopsies are frequently observed in patients with chronic diarrhoea or unspecific abdominal symptoms, potentially leading to a diagnosis of mast cell activation syndrome. However, the clinical relevance of MC quantification in this setting remains controversial. Aim: This study aimed to determine the proportion of patients with elevated MC counts who presented with diarrhoea compared to those with normal counts. As a secondary endpoint, we assessed how often MC quantification was performed and what the underlying clinical indications were. Methods: We analysed a large US national pathology database with 3.3 million colonoscopies performed between January 2009 and December 2023. Screening colonoscopies for colon cancer detection were excluded. For patients with multiple colonoscopies, only the first procedure was included. This resulted in a total of 2,059,147 colonoscopies. Results: Colonic mast cells were evaluated in 3508 reports (0.17%). In 1167 cases the report contained either the expressions indicating increased MC, or a MC count > 20 MC/high power field (hpf). Diarrhoea was present in 58.3%, 54.1%, 54.7%, 50.0% and 33.3% of patients with MC count of < 20/hpf, 20–39/hpf, 40–59/hpf, 60–98/hpf and ≥ 99/hpf, respectively. Conclusion: These data do not show a relationship between diarrhoea and elevated MC in the colonic mucosa. Therefore, we suggest that the incorporation of MC quantification into the histologic evaluation of colonoscopic biopsies obtained for common GI indications may not be warranted.
- 27 October 2026
- Published by Wiley in Alimentary Pharmacology & Therapeutics
Open AccessColonic Mast Cell Density and Diarrhoea: Evidence Against a Threshold Effect in Biopsies From 3508 Patients
Background: Elevated mast cell (MC) counts in colonic biopsies are frequently observed in patients with chronic diarrhoea or unspecific abdominal symptoms, potentially leading to a diagnosis of mast cell activation syndrome. However, the clinical relevance of MC quantification in this setting remains controversial. Aim: This study aimed to determine the proportion of patients with elevated MC counts who presented with diarrhoea compared to those with normal counts. As a secondary endpoint, we assessed how often MC quantification was performed and what the underlying clinical indications were. Methods: We analysed a large US national pathology database with 3.3 million colonoscopies performed between January 2009 and December 2023. Screening colonoscopies for colon cancer detection were excluded. For patients with multiple colonoscopies, only the first procedure was included. This resulted in a total of 2,059,147 colonoscopies. Results: Colonic mast cells were evaluated in 3508 reports (0.17%). In 1167 cases the report contained either the expressions indicating increased MC, or a MC count > 20 MC/high power field (hpf). Diarrhoea was present in 58.3%, 54.1%, 54.7%, 50.0% and 33.3% of patients with MC count of < 20/hpf, 20–39/hpf, 40–59/hpf, 60–98/hpf and ≥ 99/hpf, respectively. Conclusion: These data do not show a relationship between diarrhoea and elevated MC in the colonic mucosa. Therefore, we suggest that the incorporation of MC quantification into the histologic evaluation of colonoscopic biopsies obtained for common GI indications may not be warranted.
- Open Access
- 1 July 2026
- Published by SAGE Publications in Therapeutic Advances in Gastroenterology
- Vol. 19
Prevalence of dysphagia and eosinophilic esophagitis in patients with inflammatory bowel disease or type 2 inflammation: a cross-sectional multicenter screening study
Background: Eosinophilic esophagitis (EoE) is a chronic, type-2 inflammation-driven disease causing dysphagia. Although patients with other type-2 inflammatory diseases (type-2 ID) or inflammatory bowel disease (IBD) may have an increased risk of EoE, there is limited information about the prevalence of EoE in these specific populations. Objectives: This study aims to assess the prevalence of clinically relevant dysphagia as well as underlying EoE in patients with type-2 ID or IBD. Design: This is a cross-sectional, multicenter study of patients with type-2 ID (asthma, rhinosinusitis with polyposis nasi, allergic rhinitis, atopic dermatitis, Immunoglobulin E (IgE)-mediated food allergies) or IBD from the Medical University of Vienna and Floridsdorf Allergy Center. Methods: Patients were screened for esophageal dysphagia using the Brief Esophageal Dysphagia Questionnaire (BEDQ). Relevant dysphagia was defined as a BEDQ score ⩾4, or having a history of bolus impaction or emergency department visit due to dysphagia within the past year. Endoscopy with esophageal biopsies was offered to all patients with relevant dysphagia to screen for EoE. Results: A total of 687 patients (45.9% female, median age 45 years, 53.9% with IBD, 48.5% with a type 2 ID) were screened. Overall, 8.9% ( n = 61) reported relevant dysphagia. Endoscopy with biopsies was performed in 22 patients, and 18 patients had undergone endoscopy the year prior to the study. In total, 6 newly diagnosed cases of EoE were observed, while 7 patients had a known history of EoE, resulting in an overall prevalence of 13 patients (1.9%). Patients with any type-2 ID had numerically more EoE (2.7%) than patients with IBD (1.9%). Conclusion: While the prevalence of dysphagia among patients with type-2 ID and IBD may not exceed that of the general population, the prevalence of EoE in these populations may be higher than previously recognized.
- 1 July 2026
- Published by SAGE Publications in Therapeutic Advances in Gastroenterology
- Vol. 19
Open AccessPrevalence of dysphagia and eosinophilic esophagitis in patients with inflammatory bowel disease or type 2 inflammation: a cross-sectional multicenter screening study
Background: Eosinophilic esophagitis (EoE) is a chronic, type-2 inflammation-driven disease causing dysphagia. Although patients with other type-2 inflammatory diseases (type-2 ID) or inflammatory bowel disease (IBD) may have an increased risk of EoE, there is limited information about the prevalence of EoE in these specific populations. Objectives: This study aims to assess the prevalence of clinically relevant dysphagia as well as underlying EoE in patients with type-2 ID or IBD. Design: This is a cross-sectional, multicenter study of patients with type-2 ID (asthma, rhinosinusitis with polyposis nasi, allergic rhinitis, atopic dermatitis, Immunoglobulin E (IgE)-mediated food allergies) or IBD from the Medical University of Vienna and Floridsdorf Allergy Center. Methods: Patients were screened for esophageal dysphagia using the Brief Esophageal Dysphagia Questionnaire (BEDQ). Relevant dysphagia was defined as a BEDQ score ⩾4, or having a history of bolus impaction or emergency department visit due to dysphagia within the past year. Endoscopy with esophageal biopsies was offered to all patients with relevant dysphagia to screen for EoE. Results: A total of 687 patients (45.9% female, median age 45 years, 53.9% with IBD, 48.5% with a type 2 ID) were screened. Overall, 8.9% ( n = 61) reported relevant dysphagia. Endoscopy with biopsies was performed in 22 patients, and 18 patients had undergone endoscopy the year prior to the study. In total, 6 newly diagnosed cases of EoE were observed, while 7 patients had a known history of EoE, resulting in an overall prevalence of 13 patients (1.9%). Patients with any type-2 ID had numerically more EoE (2.7%) than patients with IBD (1.9%). Conclusion: While the prevalence of dysphagia among patients with type-2 ID and IBD may not exceed that of the general population, the prevalence of EoE in these populations may be higher than previously recognized.
- Open Access
- 19 June 2026
- Published by Oxford University Press (OUP) in Crohn's & Colitis 360
- Vol. 8 (2) , otag064
Stoma formation and associated risk factors in patients with Crohn′s disease in an Austrian tertiary referral hospital: A retrospective explorative study of long-term follow-up
Background: The cumulative probability of patients with Crohn’s disease (CD) requiring a stoma at a tertiary center is unknown. We sought to evaluate the time to stoma formation after diagnosis as well as risk factors for stoma formation in CD patients. Methods: This is a retrospective, longitudinal cohort study on consecutive patients with CD at an Austrian tertiary referral university center. In brief, patients with CD were identified and disease-specific data were captured prior to June 2023. The probability of stoma-free survival by subgroups of various potential risk factors was assessed by means of Kaplan-Meier estimates (Log-rank test). Results: Of 1267 CD patients, 142 (11.2%) underwent a stoma formation (80 ileostomies, 62 colostomies), of which 51 (35.9%) were permanent stomas. The probability of stoma-free survival at 10 and 20 years after diagnosis was 92% and 86%, respectively. Ileocolonic and colonic location, penetrating behavior, and perianal disease were associated with a higher risk for stoma formation (each p < 0.001). If these risk factors coincided, the probability of stoma-free survival at 10 and 20 years after diagnosis was only 76.4% and 67.2%, respectively. Patients diagnosed from 2000 onwards had a trend for a lower stoma risk than patients diagnosed earlier (p = 0.084). Conclusions: The coincidence of colonic or ileocolonic involvement, penetrating behaviour and perianal fistulas significantly reduced the probability of stoma-free survival to 68% 20 years after diagnosis. Identification of these risk factors for stoma formation may help identify patients at risk and thus raise awareness for this group.
- 19 June 2026
- Published by Oxford University Press (OUP) in Crohn's & Colitis 360
- Vol. 8 (2) , otag064
Open AccessStoma formation and associated risk factors in patients with Crohn′s disease in an Austrian tertiary referral hospital: A retrospective explorative study of long-term follow-up
Background: The cumulative probability of patients with Crohn’s disease (CD) requiring a stoma at a tertiary center is unknown. We sought to evaluate the time to stoma formation after diagnosis as well as risk factors for stoma formation in CD patients. Methods: This is a retrospective, longitudinal cohort study on consecutive patients with CD at an Austrian tertiary referral university center. In brief, patients with CD were identified and disease-specific data were captured prior to June 2023. The probability of stoma-free survival by subgroups of various potential risk factors was assessed by means of Kaplan-Meier estimates (Log-rank test). Results: Of 1267 CD patients, 142 (11.2%) underwent a stoma formation (80 ileostomies, 62 colostomies), of which 51 (35.9%) were permanent stomas. The probability of stoma-free survival at 10 and 20 years after diagnosis was 92% and 86%, respectively. Ileocolonic and colonic location, penetrating behavior, and perianal disease were associated with a higher risk for stoma formation (each p < 0.001). If these risk factors coincided, the probability of stoma-free survival at 10 and 20 years after diagnosis was only 76.4% and 67.2%, respectively. Patients diagnosed from 2000 onwards had a trend for a lower stoma risk than patients diagnosed earlier (p = 0.084). Conclusions: The coincidence of colonic or ileocolonic involvement, penetrating behaviour and perianal fistulas significantly reduced the probability of stoma-free survival to 68% 20 years after diagnosis. Identification of these risk factors for stoma formation may help identify patients at risk and thus raise awareness for this group.
- Open Access
- 12 May 2026
- Published by Oxford University Press (OUP) in Diseases of the Esophagus
- Vol. 39 (3)
Treatment patterns of eosinophilic esophagitis in the biologic era—a real-world analysis
Summary: Eosinophilic esophagitis is a chronic immune-mediated disease requiring a long-term maintenance treatment. The data on therapy patterns and treatment durability in the biologic era are scarce in a real-world setting. The aim of this project was to provide information on the treatment courses in a real-world setting over past 10 years. Data on demographics, concomitant atopic diseases and treatments were collected retrospectively at seven Austrian centres. The eligible subjects had to start their first therapy between January 2014 and February 2025. In total, 336 patients (30.1% female) were analyzed of whom 34.5% remained on the first line treatment. In a mean time of 7.6 months, a second line treatment was started. The most common first line treatment was swallowed topical corticosteroids (STCs) (54.2%), followed by proton pump inhibitors (22.3%) and food elimination diet (6.0%). In contrast to only a minority who continued on PPI therapy after starting it (21.3%), the majority of patients had ongoing STC treatment (51%). Forty-one (12.2%) patients received a treatment with dupilumab of whom only one as first line treatment (because of multiple type 2 inflammatory diseases) and the majority as second line treatment (57.5%). The reasons for dupilumab were non-response to STC (59%), followed by side effects (24%). 97.6% (40/41) of them remained on dupilumab until the last follow-up. Although most patients receive STC at the beginning, the majority need multiple treatment lines. Dupilumab is used in a tenth of patients due to refractoriness, side-effects or treatment of other type 2 inflammatory diseases.
- 12 May 2026
- Published by Oxford University Press (OUP) in Diseases of the Esophagus
- Vol. 39 (3)
Open AccessTreatment patterns of eosinophilic esophagitis in the biologic era—a real-world analysis
Summary: Eosinophilic esophagitis is a chronic immune-mediated disease requiring a long-term maintenance treatment. The data on therapy patterns and treatment durability in the biologic era are scarce in a real-world setting. The aim of this project was to provide information on the treatment courses in a real-world setting over past 10 years. Data on demographics, concomitant atopic diseases and treatments were collected retrospectively at seven Austrian centres. The eligible subjects had to start their first therapy between January 2014 and February 2025. In total, 336 patients (30.1% female) were analyzed of whom 34.5% remained on the first line treatment. In a mean time of 7.6 months, a second line treatment was started. The most common first line treatment was swallowed topical corticosteroids (STCs) (54.2%), followed by proton pump inhibitors (22.3%) and food elimination diet (6.0%). In contrast to only a minority who continued on PPI therapy after starting it (21.3%), the majority of patients had ongoing STC treatment (51%). Forty-one (12.2%) patients received a treatment with dupilumab of whom only one as first line treatment (because of multiple type 2 inflammatory diseases) and the majority as second line treatment (57.5%). The reasons for dupilumab were non-response to STC (59%), followed by side effects (24%). 97.6% (40/41) of them remained on dupilumab until the last follow-up. Although most patients receive STC at the beginning, the majority need multiple treatment lines. Dupilumab is used in a tenth of patients due to refractoriness, side-effects or treatment of other type 2 inflammatory diseases.
- Open Access
- 1 September 2025
- Published by Oxford University Press (OUP) in Diseases of the Esophagus
- Vol. 38 (5)
Wide discrepancy between best practice recommendations and real-life management of suspected eosinophilic esophagitis-associated food bolus impaction
SUMMARY: Esophageal food impaction (EFI) is the leading complication in patients with undiagnosed eosinophilic esophagitis (EoE). Limited data exists on pre-hospital care, in-hospital management, and post-hospital follow-up in suspected EoE-associated EFI. This study aims to assess deviations between real-life management and guideline-based recommendations in suspected EoE-associated EFI. This retrospective multicenter study analyzed data from four major Swiss gastroenterology units on patients with EoE-associated EFI. Patients with GERD-related strictures or esophageal cancer were excluded. Data on demographics, emergency department (ED), endoscopy management, and follow-up were obtained from electronic health records. Associations between clinical factors and odds of biopsy were analyzed using logistic regression. Between January 2015 and December 2020, 198 EFI cases (median age 51 years, 29.8% female, 28% with previous EFI) were recorded. Patient delay—the time between symptom onset and ED admission—was ~ 270 minutes. Nearly all patients (94%) required endoscopic bolus removal. The median time from ED presentation to endoscopy was ~150 minutes. Esophageal biopsies were taken in just over half of the individuals (n = 97, 52%), leading to a new EoE diagnosis in 71 (68.9% of those biopsied). Biopsy odds decreased significantly with older age (OR 0.96; 95% CI 0.94–0.98, P < 0.05) and known EoE (OR 0.26; 95% 0.09–0.69, P < 0.05). Although EoE is a leading cause of EFI, too few patients with a high baseline probability of EoE undergo biopsy in the emergency setting. Among those biopsied, the majority received a new EoE diagnosis, highlighting the importance of histological assessment.
- 1 September 2025
- Published by Oxford University Press (OUP) in Diseases of the Esophagus
- Vol. 38 (5)
Open AccessWide discrepancy between best practice recommendations and real-life management of suspected eosinophilic esophagitis-associated food bolus impaction
SUMMARY: Esophageal food impaction (EFI) is the leading complication in patients with undiagnosed eosinophilic esophagitis (EoE). Limited data exists on pre-hospital care, in-hospital management, and post-hospital follow-up in suspected EoE-associated EFI. This study aims to assess deviations between real-life management and guideline-based recommendations in suspected EoE-associated EFI. This retrospective multicenter study analyzed data from four major Swiss gastroenterology units on patients with EoE-associated EFI. Patients with GERD-related strictures or esophageal cancer were excluded. Data on demographics, emergency department (ED), endoscopy management, and follow-up were obtained from electronic health records. Associations between clinical factors and odds of biopsy were analyzed using logistic regression. Between January 2015 and December 2020, 198 EFI cases (median age 51 years, 29.8% female, 28% with previous EFI) were recorded. Patient delay—the time between symptom onset and ED admission—was ~ 270 minutes. Nearly all patients (94%) required endoscopic bolus removal. The median time from ED presentation to endoscopy was ~150 minutes. Esophageal biopsies were taken in just over half of the individuals (n = 97, 52%), leading to a new EoE diagnosis in 71 (68.9% of those biopsied). Biopsy odds decreased significantly with older age (OR 0.96; 95% CI 0.94–0.98, P < 0.05) and known EoE (OR 0.26; 95% 0.09–0.69, P < 0.05). Although EoE is a leading cause of EFI, too few patients with a high baseline probability of EoE undergo biopsy in the emergency setting. Among those biopsied, the majority received a new EoE diagnosis, highlighting the importance of histological assessment.
- Open Access
- 21 May 2025
- Published by Springer Nature in Wiener klinische Wochenschrift
- Vol. 137 (23-24) , 768-773
No increase of biopsy rates despite high rates of probable eosinophilic esophagitis in patients with esophageal food impaction
Summary: Introduction: Eosinophilic esophagitis (EoE) is one of the main causes of esophageal food impaction (EFI). Since only few endoscopists take biopsies during the emergency endoscopy at EFI presentation, as is recommended by current guidelines, a high number of patients will not have a proper diagnosis after EFI. Hence, we investigated the change of biopsy rates and the etiology of EFI over 11 years. Methods: All patients presenting at the emergency department (ED) of a tertiary center with an EFI who underwent esophagogastroduodenoscopy (EGD) between 2013 and 2023 were included. Clinical and endoscopic variables were analyzed retrospectively. We performed a binary logistic regression model to predict biopsy performance. Results: A total of 180 EFI cases (67% male, median age 57 years) were recorded between 2013 and 2023. Overall, esophageal biopsies were taken only in 18% without any increase over time. In patients ≥ 50 years of age ( n = 108), the etiology remained unknown in half of patients (48%), followed by gastroesophageal reflux disease (GERD; 23%) and EoE (18%). However, in patients < 50 years of age, EoE was the main suspected etiology in 69% of cases. Biopsies were obtained in only 18% of all patients with suspected EoE. Age, gender, and the year of EFI were not associated with biopsy performance. However, the probability of biopsy increased by a factor of 4.03 in the presence of suspected EoE by the endoscopist. Conclusion: Despite an increasing awareness of EoE, the biopsy rate in EFI is rather low. Routine biopsies should be taken to shorten diagnostic delay.
- 21 May 2025
- Published by Springer Nature in Wiener klinische Wochenschrift
- Vol. 137 (23-24) , 768-773
Open AccessNo increase of biopsy rates despite high rates of probable eosinophilic esophagitis in patients with esophageal food impaction
Summary: Introduction: Eosinophilic esophagitis (EoE) is one of the main causes of esophageal food impaction (EFI). Since only few endoscopists take biopsies during the emergency endoscopy at EFI presentation, as is recommended by current guidelines, a high number of patients will not have a proper diagnosis after EFI. Hence, we investigated the change of biopsy rates and the etiology of EFI over 11 years. Methods: All patients presenting at the emergency department (ED) of a tertiary center with an EFI who underwent esophagogastroduodenoscopy (EGD) between 2013 and 2023 were included. Clinical and endoscopic variables were analyzed retrospectively. We performed a binary logistic regression model to predict biopsy performance. Results: A total of 180 EFI cases (67% male, median age 57 years) were recorded between 2013 and 2023. Overall, esophageal biopsies were taken only in 18% without any increase over time. In patients ≥ 50 years of age ( n = 108), the etiology remained unknown in half of patients (48%), followed by gastroesophageal reflux disease (GERD; 23%) and EoE (18%). However, in patients < 50 years of age, EoE was the main suspected etiology in 69% of cases. Biopsies were obtained in only 18% of all patients with suspected EoE. Age, gender, and the year of EFI were not associated with biopsy performance. However, the probability of biopsy increased by a factor of 4.03 in the presence of suspected EoE by the endoscopist. Conclusion: Despite an increasing awareness of EoE, the biopsy rate in EFI is rather low. Routine biopsies should be taken to shorten diagnostic delay.
- 31 March 2025
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 121 (1) , 130-139
Loss of Response to Off-Label Swallowed Topical Corticosteroids in Eosinophilic Esophagitis Can be Overcome by a Switch to an Esophageal-Targeted Budesonide Formulation
INTRODUCTION: Swallowed topical corticosteroids (STCs) are effective in treating patients with eosinophilic esophagitis. However, real-world data about loss of response to STC are limited and whether patients with off-label STC (olSTC) failure may achieve histologic remission after a switch to budesonide orodispersible tablets (BOT) is unknown. METHODS: We analyzed prospectively collected data between 2015 and 2023 from the Swiss Eosinophilic Esophagitis Cohort Study and compared patients with prior histologic olSTC-failure (≥15 eosinophils per high-power field), histologic remission after olSTC (P = 0.002), off-label STC adherence P = 0.03), and age P = 0.004) were independently associated with histologic nonresponse to olSTC. Histologic or combined remission to BOT was not different in patients with prior olSTC response (n = 44) compared to patients nonresponded to olSTC (n = 66) (77.3% vs 62.1%, P = 0.095 and 61.4% vs 42.4%, P = 0.052). DISCUSSION: Most patients nonresponding to olSTC are not true corticosteroid-refractory but respond to an esophageal-targeted budesonide formulation. Age below 30 years, longer treatment duration and low adherence are associated with olSTC-failure.
- 31 March 2025
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 121 (1) , 130-139
Loss of Response to Off-Label Swallowed Topical Corticosteroids in Eosinophilic Esophagitis Can be Overcome by a Switch to an Esophageal-Targeted Budesonide Formulation
INTRODUCTION: Swallowed topical corticosteroids (STCs) are effective in treating patients with eosinophilic esophagitis. However, real-world data about loss of response to STC are limited and whether patients with off-label STC (olSTC) failure may achieve histologic remission after a switch to budesonide orodispersible tablets (BOT) is unknown. METHODS: We analyzed prospectively collected data between 2015 and 2023 from the Swiss Eosinophilic Esophagitis Cohort Study and compared patients with prior histologic olSTC-failure (≥15 eosinophils per high-power field), histologic remission after olSTC (P = 0.002), off-label STC adherence P = 0.03), and age P = 0.004) were independently associated with histologic nonresponse to olSTC. Histologic or combined remission to BOT was not different in patients with prior olSTC response (n = 44) compared to patients nonresponded to olSTC (n = 66) (77.3% vs 62.1%, P = 0.095 and 61.4% vs 42.4%, P = 0.052). DISCUSSION: Most patients nonresponding to olSTC are not true corticosteroid-refractory but respond to an esophageal-targeted budesonide formulation. Age below 30 years, longer treatment duration and low adherence are associated with olSTC-failure.
- Open Access
- 1 January 2025
- Published by S. Karger AG in Inflammatory Intestinal Diseases
- Vol. 10 (1) , 155-160
Long-Term Outcome of Ciclosporin and Infliximab as Rescue Therapy in Steroid-Refractory Acute Severe Ulcerative Colitis
Background: Ciclosporin and infliximab have equal short-term efficacy in treating acute severe ulcerative colitis (ASUC). However, data about long-term outcome and switching to a second rescue therapy are limited. Methods: Patients with steroid-refractory ASUC treated at a tertiary center in Switzerland were retrospectively analyzed regarding the outcome of different rescue therapies. Colectomy-free survival rates at 1, 3, and 5 years were estimated through Kaplan-Meier method. Furthermore, predictors of colectomy, the presence of adverse events at 1 year and mortality during the entire follow-up were assessed. Results: We analyzed a total of 46 patients who were treated initially with either ciclosporin (n = 31) or infliximab (n = 15) due to steroid-refractory ASUC between January 2010 and July 2021. A total of 13% patients received a second rescue therapy. In sum, 78%, 67%, and 48% were colectomy-free at 1, 3, and 5 years, respectively. Although there was a significant difference between the three arms in colectomy-free survival (p = 0.026), a post hoc analysis could not demonstrate a difference between each individual therapy compared to another. The post hoc analysis indicated a nonsignificant benefit with sequential therapy in comparison to ciclosporin (CsA) regarding the colectomy-free survival (p = 0.087). The outcome between infliximab and CsA was not statistically different (p = 0.149). The number of previous advanced therapies was negatively associated with 1-year colectomy-free survival (p = 0.049). Other variables such as age at hospitalization, sex, dose of steroids, disease duration, and albumin did not correlate with a higher risk of 1-year colectomy. Conclusions: This real-world single-center analysis confirms the equal efficacy and safety of infliximab and ciclosporin over a follow-up of 5 years. Patients not responding to the first may benefit of a second rescue therapy without increasing the risk of complication or mortality.
- 1 January 2025
- Published by S. Karger AG in Inflammatory Intestinal Diseases
- Vol. 10 (1) , 155-160
Open AccessLong-Term Outcome of Ciclosporin and Infliximab as Rescue Therapy in Steroid-Refractory Acute Severe Ulcerative Colitis
Background: Ciclosporin and infliximab have equal short-term efficacy in treating acute severe ulcerative colitis (ASUC). However, data about long-term outcome and switching to a second rescue therapy are limited. Methods: Patients with steroid-refractory ASUC treated at a tertiary center in Switzerland were retrospectively analyzed regarding the outcome of different rescue therapies. Colectomy-free survival rates at 1, 3, and 5 years were estimated through Kaplan-Meier method. Furthermore, predictors of colectomy, the presence of adverse events at 1 year and mortality during the entire follow-up were assessed. Results: We analyzed a total of 46 patients who were treated initially with either ciclosporin (n = 31) or infliximab (n = 15) due to steroid-refractory ASUC between January 2010 and July 2021. A total of 13% patients received a second rescue therapy. In sum, 78%, 67%, and 48% were colectomy-free at 1, 3, and 5 years, respectively. Although there was a significant difference between the three arms in colectomy-free survival (p = 0.026), a post hoc analysis could not demonstrate a difference between each individual therapy compared to another. The post hoc analysis indicated a nonsignificant benefit with sequential therapy in comparison to ciclosporin (CsA) regarding the colectomy-free survival (p = 0.087). The outcome between infliximab and CsA was not statistically different (p = 0.149). The number of previous advanced therapies was negatively associated with 1-year colectomy-free survival (p = 0.049). Other variables such as age at hospitalization, sex, dose of steroids, disease duration, and albumin did not correlate with a higher risk of 1-year colectomy. Conclusions: This real-world single-center analysis confirms the equal efficacy and safety of infliximab and ciclosporin over a follow-up of 5 years. Patients not responding to the first may benefit of a second rescue therapy without increasing the risk of complication or mortality.
- Open Access
Efficacy and Safety of Anthocyanin-Rich Extract in Patients with Ulcerative Colitis: A Randomized Controlled Trial
Background: Bilberries are effective in inducing clinical, endoscopic, and biochemical improvement in ulcerative colitis (UC) patients. The aim of this study was to investigate the efficacy of anthocyanin-rich extract (ACRE), the bioactive ingredient of bilberries, in a controlled clinical trial in moderate-to-severe UC. Methods: A multi-center, randomized, placebo-controlled, double-blind study with a parallel group was conducted. Initially, the study was planned for 100 patients; nevertheless, it prematurely ended due to COVID-19. Patients had moderate-to-severe active UC at screening (a Mayo score of 6–12, an endoscopic sub-score ≥ 2) and were randomized at baseline. The primary endpoint was a clinical response (week 8, a total Mayo score reduction ≥ 3 points). Fecal calprotectin (FC) and a centrally read endoscopic response were among the secondary endpoints. Results: Out of 48 patients (6 Swiss centers), 34 were randomized. Eighteen ACRE and eight placebo patients could be analyzed (per protocol set). Half (9/18) of ACRE patients and 3/8 of placebo patients responded clinically (p = 0.278). An improvement in the Mayo score was observed in the ACRE arm (77.8% vs. 62.5% placebo). FC dropped from 1049 ± 1139 to 557 ± 756 μg/g for ACRE but not for the placebo group (947 ± 1039 to 1040 ± 1179; p = 0.035). Serious adverse events were rare. Conclusions: ACRE treatment did not yield significant superiority to the placebo. Furthermore, the placebo response was unusually high. Moreover, there was a significant calprotectin decrease at the end of treatment, indicative of ACRE efficacy in UC.
Open AccessEfficacy and Safety of Anthocyanin-Rich Extract in Patients with Ulcerative Colitis: A Randomized Controlled Trial
Background: Bilberries are effective in inducing clinical, endoscopic, and biochemical improvement in ulcerative colitis (UC) patients. The aim of this study was to investigate the efficacy of anthocyanin-rich extract (ACRE), the bioactive ingredient of bilberries, in a controlled clinical trial in moderate-to-severe UC. Methods: A multi-center, randomized, placebo-controlled, double-blind study with a parallel group was conducted. Initially, the study was planned for 100 patients; nevertheless, it prematurely ended due to COVID-19. Patients had moderate-to-severe active UC at screening (a Mayo score of 6–12, an endoscopic sub-score ≥ 2) and were randomized at baseline. The primary endpoint was a clinical response (week 8, a total Mayo score reduction ≥ 3 points). Fecal calprotectin (FC) and a centrally read endoscopic response were among the secondary endpoints. Results: Out of 48 patients (6 Swiss centers), 34 were randomized. Eighteen ACRE and eight placebo patients could be analyzed (per protocol set). Half (9/18) of ACRE patients and 3/8 of placebo patients responded clinically (p = 0.278). An improvement in the Mayo score was observed in the ACRE arm (77.8% vs. 62.5% placebo). FC dropped from 1049 ± 1139 to 557 ± 756 μg/g for ACRE but not for the placebo group (947 ± 1039 to 1040 ± 1179; p = 0.035). Serious adverse events were rare. Conclusions: ACRE treatment did not yield significant superiority to the placebo. Furthermore, the placebo response was unusually high. Moreover, there was a significant calprotectin decrease at the end of treatment, indicative of ACRE efficacy in UC.
- Open Access
- 8 August 2024
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 69 (10) , 3853-3862
Odynophagia and Retrosternal Pain Are Common in Eosinophilic Esophagitis and Associated with an Increased Overall Symptom Severity
Background and Aims Dysphagia is the hallmark symptom in eosinophilic esophagitis (EoE). However, data are limited regarding the overall prevalence and potential implications of atypical symptoms like odynophagia and retrosternal pain. Methods Patients enrolled into the Swiss EoE cohort study (SEECS) were analyzed regarding the presence of odynophagia and retrosternal pain. Demographics, other EoE-related symptoms, histologic and endoscopic activity were compared between EoE-patients with vs. without odynophagia and/or retrosternal pain. Results 474 patients (75.2% male) were analyzed. In their individual course of disease 110 (23.2%) patients stated to have ever experienced odynophagia and 64 (13.5%) retrosternal pain independent of food intake, 24 (5%) patients complained about both symptoms. Patients with odynophagia consistently scored higher in symptom severity (p < 0.001), EREFS score (median 3.0 vs. 2.0, p = 0.006), histologic activity and a lower quality of life (p = 0.001) compared to patients without odynophagia. Sex, age at diagnosis, EoE-specific treatment, complications such as candida or viral esophagitis and disease duration were similar in patients with vs. without odynophagia. Also patients with retrosternal pain scored higher in symptom severity (2.0 vs. 1.0, p = 0.001 and 2.0 vs. 1.0, p < 0.001 in physician and patient questionnaire assessment, respectively). However, there was neither a difference in endoscopic/histologic disease activity nor in quality of life according to presence or absence of retrosternal pain. Due to logistic reasons, a stratification regarding the presence of concomitant dysphagia was not possible. Conclusion Odynophagia and swallowing-independent retrosternal pain are common symptoms in patients with EoE, associate with an overall higher EoE-related symptom severity and for the case of odynophagia lower quality of life. However, the influence of concomitant dysphagia and its severity remains unclear and needs to be included in future analyses.
- 8 August 2024
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 69 (10) , 3853-3862
Open AccessOdynophagia and Retrosternal Pain Are Common in Eosinophilic Esophagitis and Associated with an Increased Overall Symptom Severity
Background and Aims Dysphagia is the hallmark symptom in eosinophilic esophagitis (EoE). However, data are limited regarding the overall prevalence and potential implications of atypical symptoms like odynophagia and retrosternal pain. Methods Patients enrolled into the Swiss EoE cohort study (SEECS) were analyzed regarding the presence of odynophagia and retrosternal pain. Demographics, other EoE-related symptoms, histologic and endoscopic activity were compared between EoE-patients with vs. without odynophagia and/or retrosternal pain. Results 474 patients (75.2% male) were analyzed. In their individual course of disease 110 (23.2%) patients stated to have ever experienced odynophagia and 64 (13.5%) retrosternal pain independent of food intake, 24 (5%) patients complained about both symptoms. Patients with odynophagia consistently scored higher in symptom severity (p < 0.001), EREFS score (median 3.0 vs. 2.0, p = 0.006), histologic activity and a lower quality of life (p = 0.001) compared to patients without odynophagia. Sex, age at diagnosis, EoE-specific treatment, complications such as candida or viral esophagitis and disease duration were similar in patients with vs. without odynophagia. Also patients with retrosternal pain scored higher in symptom severity (2.0 vs. 1.0, p = 0.001 and 2.0 vs. 1.0, p < 0.001 in physician and patient questionnaire assessment, respectively). However, there was neither a difference in endoscopic/histologic disease activity nor in quality of life according to presence or absence of retrosternal pain. Due to logistic reasons, a stratification regarding the presence of concomitant dysphagia was not possible. Conclusion Odynophagia and swallowing-independent retrosternal pain are common symptoms in patients with EoE, associate with an overall higher EoE-related symptom severity and for the case of odynophagia lower quality of life. However, the influence of concomitant dysphagia and its severity remains unclear and needs to be included in future analyses.